American Journal of Clinical Dermatology American Journal of Clinical Dermatology RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
ConclusionThese results support dupilumab as continuous long-term treatment for adults with moderate-to-severe AD; efficacy was sustained following transition from qw to q2w dosing.Trial Registration ClinicalTrials.govNCT01949311. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 1, 2022 Category: Dermatology Source Type: research

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
AbstractBaricitinib (Olumiant®) is an oral small molecule inhibitor of Janus kinase (JAK)1 and JAK2, which have been implicated in the pathogenesis of atopic dermatitis (AD). In phase III studies in adults with moderate to severe AD who were inadequately controlled with topical corticosteroids (TCS) or systemic treatments (e.g. ciclosporin), or for whom these therapies were not advisable, baricitinib, alone or in combination with TCS, achieved significant and/or clinically relevant improvements in multiple measures of disease severity, pruritus, skin pain, sleep disturbance and health-related quality of life (HR-QOL) over...
Source: American Journal of Clinical Dermatology - May 1, 2022 Category: Dermatology Source Type: research

Correction to: A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - May 1, 2022 Category: Dermatology Source Type: research

Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review
ConclusionBiological agents are associated with a longer time to relapse than oral systemic agents after drug discontinuation. Among biologicals, IL-23 antagonists are associated with the longest time to relapse. These findings may have clinical consequences for the selection of systemic agents when intermittent treatment is necessary. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - April 30, 2022 Category: Dermatology Source Type: research

Methotrexate Cutaneous Ulceration: A Systematic Review of Cases
ConclusionMethotrexate cutaneous ulceration is commonly preceded by dosage mistakes, absence of folic acid supplementation, and concurrent use of nephrotoxic medications. Renal impairment, pancytopenia, and absence of folic acid supplementation are key risk factors for mortality from this adverse medication reaction. Providers should regularly monitor methotrexate dosing adherence, drug –drug interactions, and perform routine laboratory evaluation. Index of suspicion for this toxicity should remain high given the varied clinical presentation and high mortality. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - April 29, 2022 Category: Dermatology Source Type: research

Correction to: A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - April 22, 2022 Category: Dermatology Source Type: research

Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview
AbstractInflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal (GI) tract that is subdivided into Crohn ’s disease (CD) and ulcerative colitis (UC). CD is characterized by involvement of the entire GI tract, while UC mainly affects the distal GI tract. Moreover, both CD and UC can present with extraintestinal manifestations (EIMs) of the disease affecting multiple organ systems including the hepatob iliary tract, kidney, bones, eyes, joints, and skin. These complications can cause significant morbidity and negatively impact the quality of life for IBD patients. Although the pathogene...
Source: American Journal of Clinical Dermatology - April 20, 2022 Category: Dermatology Source Type: research

Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature
AbstractAnti-interleukin (IL)-17 agents have shown excellent therapeutic efficacy in patients with psoriasis and are expected to be expanded to other chronic inflammatory diseases. However, patients receiving anti-IL-17 agents are at an increased risk of developingCandida infection, with some agents reported to increase the incidence in a dose-dependent manner. Interleukin-17 is secreted by the Th17 subset of CD4+ lymphocytes, CD8+ T cells, and innate cells, including natural killer T cells, lymphoid tissue inducer cells, innate lymphoid cells, and γδ-T cells, and plays an important role in antifungal defense. Genetic de...
Source: American Journal of Clinical Dermatology - April 15, 2022 Category: Dermatology Source Type: research

Lessons Learned from Orthopedics: A Call to Action for More Rigorous Platelet-Rich Plasma Hair Loss Clinical Trials
(Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - April 10, 2022 Category: Dermatology Source Type: research

A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
ConclusionsUnder maximum-use conditions, ruxolitinib cream was generally well tolerated, with approximately one-third of patients experiencing treatment-emergent adverse events and few treatment-related adverse events. The mean steady-state plasma concentration of ruxolitinib was well below the level expected to affect bone marrow production of blood cells, with a small number of patients exhibiting higher plasma concentrations. In addition, ruxolitinib cream showed a high level of efficacy in patients with atopic dermatitis involving ≥ 25% affected body surface area.ClinicalTrials.gov IdentifierNCT03920852. (Source: Ame...
Source: American Journal of Clinical Dermatology - April 4, 2022 Category: Dermatology Source Type: research

Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma
AbstractIncreasing knowledge about the biology of melanoma and of immunology has led to the development and regulatory approval of the immune checkpoint inhibitors ipilimumab, nivolumab, and pembrolizumab, which are indicated for the treatment of melanoma irrespective of the B-Raf proto-oncogene mutation status of the tumour. Only a subset of patients will respond, but those who do can expect long-lasting, previously unheard-of responses. Long-term survival results for the registration trials, including CheckMate 067, Keynote-006, and Keynote-001, have recently been published. In particular, the combination of ipilimumab a...
Source: American Journal of Clinical Dermatology - March 31, 2022 Category: Dermatology Source Type: research

Patient and Public Involvement in Dermatology Research: A Review
AbstractPatient and public involvement (PPI) in research is defined as research being carried out ‘with’ or ‘by’ members of the public, patients, and carers, on both an individual and a group level, rather than simply ‘about’, or ‘for’ them. Within dermatology, PPI is increasingly recognised as a vital component of research as it helps to ensure that research remains relevant to the populations we intend to serve. Dermatology scholarship, with its rich psychosocial implications due to the stigma, physical disability, and mental health burdens these conditions may incur, is in a unique position to benefit fr...
Source: American Journal of Clinical Dermatology - March 29, 2022 Category: Dermatology Source Type: research